Treating these remains a challenge, despite the availability of immune checkpoint blockade (ICB) and v-RAF murine sarcoma viral oncogene homolog B1 (BRAF)-/mitogen-activated protein kinase kinase (MEK) inhibitors (BRAF/MEKi), as a majority of patients with advanced melanoma still succumb to disease progression. This evidence concerns the gene BRAF and melanoma.